14950 Federal Register / Vol. 60, No. 54 / Tuesday, March 21, 1995 / Notices

through the Superintendent of

Documents, Government Printing

Office, Washington, DC 20402–9325,

telephone (202) 783–3238.

Dated: March 15, 1995.

Linda Rosenstock,

Director, National Institute for Occupational

Safety and Health, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 95–6861 Filed 3–20–95; 8:45 am]

BILLING CODE 4163–19–P

Food and Drug Administration

[Docket No. 95G–0039]

Degussa Corp.; Filing of Petition for

Affirmation of GRAS Status

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Degussa Corp. has filed a petition

(GRAS 2419) proposing that

hydrophobic silica, prepared by the

hydrophobization of silicon dioxide

with dichlorodimethyl-silane, be

affirmed as generally recognized as safe

(GRAS) as an anticaking/free-flow agent

in vitamin preparations for animal feed.

DATES: Written comments by June 5,

1995.

ADDRESSES: Submit written comments

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, rm. 1–23, 12420

Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: J. D.

McCurdy, Center for Veterinary

Medicine (HFV–226), Food and Drug

Administration, 7500 Standish Pl.,

Rockville, MD 20855, 301–594–1731.

SUPPLEMENTARY INFORMATION: Under the

Federal Food, Drug, and Cosmetic Act

(sec. 201(s), 409(b)(5) (21 U.S.C. 321(s)

and 348(b)(5)) and the regulations for

affirmation of GRAS status in § 570.35

(21 CFR 570.35), notice is given that

Degussa Corp., c/o Counsel for

Petitioner, Jerome H. Heckman, Keller,

and Heckman, 1001 G St. NW., Suite

500 West, Washington, DC 20001, has

filed a petition (GRASP 2419) proposing

that hydrophobic silica, prepared by the

hydrophobization of silicon dioxide

with dichlorodimethyl-silane, be

affirmed as GRAS as an anticaking/freeflow agent in vitamin preparations for

animal feed.

The petition has been placed on

display at the Dockets Management

Branch (address above).

Any petition that meets the

requirements outlined in §§ 570.30 (21

CFR 570.30) and 570.35 is filed by the

agency. There is no prefiling review of

the adequacy of data to support a GRAS

conclusion. Thus, the filing of a petition

for GRAS affirmation should not be

interpreted as a preliminary indication

of suitability for GRAS affirmation.

The potential environmental impact

of this action is being reviewed. If the

agency finds that an environmental

impact statement is not required and

this petition results in a regulation, the

notice of availability of the agency’s

finding of no significant impact and the

evidence supporting that finding will be

published with the regulation in the

Federal Register in accordance with 21

CFR 25.40(c).

Interested persons may, on or before

June 5, 1995, review the petition and

file comments with the Dockets

Management Branch (address above).

Two copies of any comments should be

filed and should be identified with the

docket number found in brackets in the

heading of this document. Comments

should include any available

information that would be helpful in

determining whether the substance is,

or is not, GRAS for the proposed use. In

addition, consistent with the regulations

promulgated under the National

Environmental Policy Act (40 CFR

1501.4(b)), the agency encourages public

participation by review of and comment

on the environmental assessment

submitted with the petition that is the

subject of this notice. A copy of the

petition (including the environmental

assessment) and

received comments may be seen in the

Dockets Management Branch between 9

a.m. and 4 p.m., Monday through

Friday.

Dated: March 8, 1995.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 95–6918 Filed 3–20–95; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committee Meeting;

Amendment of Notice

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing an

amendment to the notice of meeting of

the Arthritis Advisory Committee. This

meeting was announced in the Federal

Register of February 17, 1995 (60 FR

9338). This amendment is being made to

announce the cancellation of the open

committee discussion portion of the

meeting and adjustment of the starting

time. There are no other changes. This

amendment will be announced at the

beginning of the open portion of the

meeting.

FOR FURTHER INFORMATION CONTACT:

Isaac F. Roubein, Center for Drug

Evaluation and Research (HFD–9), Food

and Drug Administration, 5600 Fishers

Lane, Rockville, MD 20857, 301–443–

5455, or FDA Advisory Committee

Information Hotline, 1–800–741–8138

(301–443–0572 in the Washington, DC

area), Arthritis Advisory Committee,

code 12532.

SUPPLEMENTARY INFORMATION: In the

Federal Register of February 17, 1995

(60 FR 9338), FDA announced that the

Arthritis Advisory Committee would

hold a meeting on March 27, 1995.

On page 9338, column 2, the ‘‘Date,

time, and place’’ portion is amended to

read as follows:

Date, time, and place. March 27,

1995, 9 a.m., Holiday Inn—Silver

Spring, Silver Room, 8777 Georgia Ave.,

Silver Spring, MD.

On page 9338, column 2, the ‘‘Type of

meeting and contact person’’ portion is

amended to read as follows:

Type of meeting and contact person.

Open public hearing, 9 a.m. to 10 a.m.,

unless public participation does not last

that long; closed committee

deliberations, 10 a.m. to 4 p.m.; Isaac F.

Roubein, Center for Drug Evaluation and

Research (HFD–9), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–5455, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area),

Arthritis Advisory Committee, code

12532.

Dated: March 16, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95–7068 Filed 3–17–95; 3:46 pm]

BILLING CODE 4160–01–F

Advisory Committee Meetings;

Amendment of Notice

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing an

amendment to the notice of meeting of

the Nonprescription Drugs Advisory

Committee. This meeting was

announced in the Federal Register of

February 17, 1995 (60 FR 9335 at 9336).

The amendment is being made to

announce the cancellation of the joint

session with the Dermatologic and

Ophthalmic Drugs Advisory Committee;

the cancellation of the session with